Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: GlobeNewswire
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage. This approach could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases that require delivery of therapeutics to the brain. About HSPCs Gene editing in hematopoietic stem and progenitor cells (HSPCs) has enabled the treatment of multiple previously uncurable genetic diseases. Edited therapeutic HSPCs can engraft in the patient’s bone marrow, self-replicate, differentiate and populate other organs, propagating the therapeutic effects systemically an
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs [Yahoo! Finance]Yahoo! Finance
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsGlobeNewswire
- SmartCella strengthens team with Dr Ricardo Baptista as CTO [Yahoo! Finance]Yahoo! Finance
- Cellectis S.A. (NASDAQ: CLLS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
CLLS
Earnings
- 11/6/23 - In-Line
CLLS
Sec Filings
- 4/22/24 - Form 6-K
- 4/10/24 - Form 6-K
- 4/8/24 - Form 6-K
- CLLS's page on the SEC website